clii Results Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed 5, 6 (b) Give reasons for non-participation at each stage 5 (c) Consider use of a flow diagram 6 Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders 5, 6 (b) Indicate number of participants with missing data for each variable of interest - (c) Summarise follow-up time (eg, average and total amount) - Outcome data 15* Report numbers of outcome events or summary measures over time 7-13 Main results 16 (a) Give unadjusted estimates and, if applicable, confounderadjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included 7-13 (b) Report category boundaries when continuous variables were categorized 5, 7-13 (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period - Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses - Discussion Key results 18 Summarise key results with reference to study objectives 15 Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias 15, 16 Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence 16 Generalisability 21 Discuss the generalisability (external validity) of the study results 16 Other information Funding 22 Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based 1
RkJQdWJsaXNoZXIy MTk4NDMw